SLC5A2 and Alzheimer disease: These epidemiological findings, combined with our mechanistic insights, suggest that SGLT2 inhibitors, particularly potent ones like Enavogliflozin, represent a promising therapeutic strategy for AD, though randomized controlled trials are needed to confirm their efficacy.